BIOLOGIC/DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD)
Simponi Aria is approved by the U.S. Food and Drug Administration (FDA) to treat adults and children over age 2 with active psoriatic arthritis. Simponi Aria is also referred to by its drug name, golimumab. Golimumab is also sold under the brand name Simponi, which has a different method of delivery.
Simponi Aria is considered a biologic disease-modifying antirheumatic drug (DMARD). Simponi Aria is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Simponi Aria is believed to work by inhibiting tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.
How do I take it?
Prescribing information states that Simponi Aria is administered as an intravenous infusion every eight weeks after initial loading doses.
Simponi Aria comes in a single-dose vial.
The FDA-approved label for Simponi Aria lists common side effects including upper respiratory tract infection, increased liver enzymes, viral infection, decreased blood cell count, bronchitis, hypertension, and rash.
Rare but serious side effects listed for Simponi Aria include severe infections, congestive heart failure, hepatitis B reinfection, increased risk for lymphoma, demyelinating disorders such as multiple sclerosis, lupus-like syndrome, and hypersensitivity reactions.
For more details about this treatment, visit:
SimponiAria.com — Janssen